Search | Clinical Trials Finder

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions: Atrial Flow Regulator, Sham Comparator; Device
Lead sponsor: Occlutech International AB; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Phoenix, Arizona • New York, New York

Conditions: Traumatic Brain Injury
Interventions: Transcranial Direct Current Stimulator (TDCS), Control Group, Healthy Control Group; Device · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Overactive Bladder, Neurogenic Bladder, Urge Incontinence, Pain, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic, Urinary Bladder Neurogenesis, Urinary Incontinence, Urge, Pelvic Floor Disorders
Interventions: Pro-Nox Nitrous Oxide/Oxygen Delivery System, Standard Care for Bladder Botox Injection, Sham Mask; Drug · Other
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Venous Stasis Ulcers
Interventions: PEMF therapy with a high-power PEMF device, PEMF therapy with a medium PEMF power device, PEMF therapy with a low-power PEMF device, PEMF therapy with the sham PEMF device; Device
Lead sponsor: PEMF Systems, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Angelman Syndrome
Interventions: GTX-102, Sham-LP; Drug · Procedure
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 11 more

Conditions: Gastroesophageal Reflux Disease, Hiatal Hernia
Interventions: TIF Transoral Fundoplication, Sham placebo procedure; Device · Other
Lead sponsor: EndoGastric Solutions; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 9
States / cities: Los Angeles, California • Englewood, Colorado • Chicago, Illinois + 5 more

Conditions: Total Knee Arthroplasty (Postoperative Pain), Total Hip Arthroplasty (Postoperative Pain)
Interventions: Transcranial Direct Current Stimulation, Cognitive-Behavioral (CB) intervention; Device · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 90 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Spinal Muscular Atrophy
Interventions: Nusinersen, Sham procedure; Drug · Procedure
Lead sponsor: Biogen; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more

Conditions: Acute Lymphoblastic Leukemia, Transcranial Direct Current Stimulation, Executive Dysfunction
Interventions: Anodal tDCS treatment, Cathodal tDCS treatment, Sham treatment, NIH Toolbox List Sorting Working Memory Test, NIH Toolbox Flanker Inhibitory Control and Attention Test, Grooved Peg Board Test, Buschke Selective Reminding Test; Device · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Years to 215 Months
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: PostTraumatic Stress Disorder
Interventions: Ropivacaine, Sham treatment; Drug
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Honolulu, Hawaii • Fort Bragg, North Carolina

Conditions: Diabetic Macular Edema
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 40
States / cities: Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more

Conditions: Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Interventions: BS01, Sham procedure control; Biological · Other
Lead sponsor: Bionic Sight LLC; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Edison, New Jersey

Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions: Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN); Device · Drug
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: New York, New York

Conditions: Ostheoporosis of the Knee
Interventions: Acupuncture, Enery Medicine Intervention, Sham Energy Medicine; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions: Renal Denervation using the Symplicity Renal Denervation System, Sham Renal Denervation, Renal Angiography; Device · Other
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Atlanta, Georgia • Durham, North Carolina • Charleston, South Carolina

Conditions: Pain
Interventions: Percutaneous radiofrequency electrical nerve stimulation, Non-therapeutic stimulation; Device
Lead sponsor: Synaptrix, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Daphne, Alabama • Williamsville, New York • Chapel Hill, North Carolina + 2 more

Conditions: Opioid Use, Opioid Use Disorder, Substance Use Disorders
Interventions: Virtual Reality Avatar Intervention, Virtual Reality Empty Park; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Indianapolis, Indiana • Coburg, Oregon

Conditions: Gastroparesis
Interventions: Endoscopic per-oral pyloromyotomy (POP), Diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption; Procedure
Lead sponsor: Matthew Allemang; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Articular Cartilage Defect Grade III or IV of the Knee
Interventions: Autologous Cell, Standard microfracture arthroscopic surgery; Procedure
Lead sponsor: Fondren Orthopedic Group L.L.P.; Other
Eligibility: 18 Years to 68 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Substance Use Disorders, Opioid Use Disorder, Alcohol Use Disorder, Cocaine Use Disorder, Methamphetamine-dependence
Interventions: EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), CBOT with olfactory stimulants & OFC tasks, CBOT Sham; Combination Product
Lead sponsor: Evon Medics LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Rockville, Maryland

Conditions: Bronchopulmonary Dysplasia
Interventions: Minimally invasive surfactant therapy, Continuation on CPAP; Device · Other
Lead sponsor: Menzies Institute for Medical Research; Other
Eligibility: 1 Minute to 6 Hours
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 5
States / cities: New Haven, Connecticut • Honolulu, Hawaii • Evanston, Illinois + 2 more

Conditions: Barrett Esophagus
Interventions: Ablation System plus anti-secretory medication, Sham procedure plus anti-secretory medication; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 19
States / cities: Scottsdale, Arizona • Tucson, Arizona • Orange, California + 15 more

Conditions: Vaginal Microflora
Interventions: Experimental - Tampon with GML, Sham Control - Tampons without GML; Device
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 482 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Scottsdale, Arizona • St. Petersburg, Florida

Conditions: Neovascular Age-related Macular Degeneration
Interventions: UBX1325 injection 50 μL, EYLEA® (aflibercept) Injection 2 mg (0.05mL); Drug
Lead sponsor: Unity Biotechnology, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 14
States / cities: Beverly Hills, California • Huntington Beach, California • Longmont, Colorado + 11 more

Search by objective public record fields.

Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study

Relationship Between Attention and Emotional Regulation Post-Traumatic Brain Injury (TBI)

A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections

The Effects of Pulsed Elelectro-Magnetic Fields ("PEMF") in the Treatment of Venous Stasis Leg Ulcers

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study

Effects of tDCS Combined With CBI on Postsurgical Pain

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)

Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

Efficacy and Mechanisms of Energy Medicine to Decrease Chronic Knee Pain in Outpatient Settings

Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4

Pivotal Study on the NOVABLOC System for Patients Undergoing Primary Total Knee Arthroplasty

Enhancing Prospective Thinking in Early Recovery (PARK)

Endoscopic Myotomy of the Pylorus To Improve Emptying and Symptoms Trial

Use of Cell Therapy to Enhance Arthroscopic Knee Cartilage Surgery

Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders

OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP

Ablation of Intestinal Metaplasia Containing Dysplasia

Clinical Evaluation of Effects of an Investigational Tampon on Vaginal Microflora

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)